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Abstract
Background: Salmonella enterica serovar Typhimurium is one of the most common enteropathogenic bacteria
found in pigs in Europe. In our previous work, we demonstrated the protective effects in suckling piglets when
their dams had been vaccinated with an S. Typhimurium-based inactivated vaccine. This study is focused on a
procedure leading to serological discrimination between vaccinated and infected pigs. As we supposed, distinct
environment during natural infection and in bacterial cultures used for vaccine preparation led to a slightly different
spectrum of expressed S. Typhimurium proteins. The examination of porcine antibodies produced after the
experimental infection with S. Typhimurium or after vaccination with S. Typhimurium-based inactivated vaccine by
affinity chromatography and mass spectrometry revealed differences in antibody response applicable for serological
differentiation of infected from vaccinated animals.
Results: Antibodies against Salmonella SipB, SipD and SseB proteins were detected at much higher levels in post-
infection sera in comparison with control and post-vaccination sera. On the other hand, proteins BamB, OppA and
a fragment of FliC interacted with antibodies from post-vaccination sera with a much higher intensity than from
control and post-infection sera. In addition, we constructed ELISA assays using post-infection antigen - SipB protein
and post-vaccination antigen - FliC-fragment and evaluated them on a panel of individual porcine sera.
Conclusions: The analysis of antibody response of infected and vaccinated pigs by proteomic tools enabled to
identify S. Typhimurium antigens useful for distinguishing infected from vaccinated animals. This approach can be
utilized in other challenges where DIVA vaccine and a subsequent serological assay are required, especially when
genetic modification of a vaccine strain is not desirable.
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Background
Infections caused by non-typhoid Salmonella enterica sero-
var Typhimurium (Salmonella Typhimurium) constitute a
persistent problem in human and veterinary medicine. Sal-
monella Typhimurium is the most frequent serotype found
in pigs. Contaminated pork and porcine products are thus
a source of infection for human consumers [1]. A possible
way to moderate the Salmonella burden in pigs is vaccin-
ation. A successful and widely used vaccine should allow
distinguishing vaccinated animals from those that were nat-
urally infected, so-called DIVA approach (Differentiating
Infected from Vaccinated individuals) [2]. Available diag-
nostic serological tests for the evaluation of Salmonella in-
fections in pigs are based on measurements of the level of
antibodies induced by O-antigens, the outer segment of
bacterial lipopolysaccharide (LPS) [3]. These assays do not
allow us to distinguish infected and vaccinated animals
when Salmonella strain without any deletion in genes re-
sponsible for lipopolysaccharide formation is used for vac-
cination [4]. On the other hand, LPS plays a role as an
inducer of the immune response, which might be beneficial
for the vaccination itself [5, 6]. Selke et al. [7] introduced a
live negative-marker vaccine based on Salmonella Typhi-
murium strain with deleted gene for the outer membrane
protein ompD. Bearson et al. [8] prepared a similar attenu-
ated live negative-marker vaccine with a deletion of mul-
tiple small regulatory RNAs combined with rfaH mutation.
However, using a genetically modified live bacterial strain
as a vaccine may be questionable because of current regula-
tion and public non-acceptance of genetically modified or-
ganisms in Europe.
With an unmodified inactivated Salmonella
Typhimurium-based vaccine for pigs developed in our pre-
vious work we achieved a similar level of protectivity for
suckling piglets [9] as Selke et al. [7]. In this study, we ex-
tend the development of this vaccine to include DIVA test-
ing. We took advantage of the fact that Salmonella express
virulence factors (proteins from SPIs - Salmonella patho-
genicity islands) in an environment-dependent manner. We
thus expected differences in bacterial protein expression
under in vitro and in vivo conditions. We analysed the anti-
body response to the vaccine based on inactivated Salmon-
ella Typhimurium cultivated in vitro and the antibody
response of animals infected with live bacteria.
Based on this, we introduced a method for discovering
Salmonella proteins able to induce condition-specific
antibody production, which allows us to serologically
distinguish animals that were vaccinated from those in-
fected with Salmonella Typhimurium.
Methods
Bacterial strain
Salmonella enterica serovar Typhimurium phage type
DT104 strain (strain number 1A5, from bacterial
collection at Veterinary Research Institute, originally iso-
lated from healthy sow), hereinafter referred to as Sal-
monella Typhimurium, was used in this experiment.
Bacteria were cultivated overnight at 37 °C in Miller's LB
Broth Base (Invitrogen, USA) or brain heart infusion
(BHI) broth (Oxoid, UK) for certain analyses as de-
scribed below.
Vaccination and infection of pigs
Three groups of animals consisting of twelve white
mixed-breed piglets (bought from a commercial stud)
weaned 21 days after birth were used in the experiment.
Pigs in the first group remained serologically negative
for anti-Salmonella antibodies (determined by Pig
Screen ELISA, Qiagen, Germany). Another twelve ani-
mals were orally infected one week after housing with
1 × 108 CFU of Salmonella Typhimurium grown in BHI
medium and blood was collected 28 days after the infec-
tion. The last group of animals was vaccinated intramus-
cularly into the neck with 1 ml of a vaccine prepared
from 1 × 109 CFU of Salmonella Typhimurium grown in
BHI medium, inactivated with formaldehyde and adju-
vanted with Montanide ISA50V2 (Seppic, France). The
first dose was administered one week after housing and
the second dose two weeks later. Blood was collected
14 days after the second dose of a vaccine.
Antibody fraction preparation
Serum samples from three random animals from each
group were pooled together and IgG fractions were iso-
lated using Protein G columns (HiTrap Protein G HP,
GE Healthcare, UK) according to the manufacturer’s
protocol. Affinity chromatography was performed on an
FPLC instrument (Pharmacia, Sweden).
Antigen preparation
The same procedure of preparing bacterial protein lysate
was used for the comparison of Salmonella Typhimurium
protein expression when cultivated in LB or BHI medium
using MS and for immunoaffinity chromatography.
Salmonella Typhimurium was grown overnight at 37 °C
in LB and BHI medium, as noted above. The culture was
then centrifuged (3,500 × g, 10 min), and a cell pellet was
washed 3 times in PBS (Dulbecco’s, Lonza, Switzerland).
The cell pellet was resuspended in PBS and sonicated
(Sonopuls HD 3100, Bandelin, Germany) with zirconia/sil-
ica beads (BioSpec Products, USA). The sonicate was cen-
trifuged at 20,000 × g and the supernatant with proteins
was taken. The pellet was then resuspended in 8 M urea
(Serva, Germany), 0.1 % SDS (Carl Roth, Germany), 2 %
Triton X-100 (Serva, Germany) and 25 mM triethylam-
monium bicarbonate (Sigma-Aldrich, USA) and centri-
fuged at 20,000 × g again. The supernatant was mixed
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with the supernatant from the previous step and together
used as an antigen for subsequent analysis.
Immunoaffinity chromatography
IgGs from all three sample groups were covalently
bound to CNBr-activated Sepharose (GE Healthcare,
UK) according to the manufacturer’s protocol. Sepharose
with bound immunoglobulins was loaded into 3 plastic
cartridges (BioRad, USA) creating liquid chromatog-
raphy columns. The same antigen (protein lysate from
Salmonella Typhimurium grown in LB) was used for all
three IgG columns - column with antibodies from nega-
tive control animals, from vaccinated animals and from
infected animals. 20 mM sodium phosphate buffer,
pH 7.0 (Serva, Germany) served as a binding buffer.
0.1 M glycine-HCl (Serva, Germany), pH 2.7 was used
for elution of bound proteins and 1 M Tris–HCl (Carl
Roth, Germany), pH 9.0, was added to collection tubes
for pH adjustment. Protein eluates were then used for
analysis by mass spectrometry.
LC-MS/MS analysis
100 μg of proteins (measured with Pierce™ BCA Protein
Assay Kit, Thermo Scientific, USA) was used for each
sample preparation with the FASP (filter-aided sample
preparation) method [10]. Each sample was washed five
times with 8 M urea (Serva, Germany) in Vivacon 500
centrifugal tubes (Sartorius Stedim, Germany) with
10,000 MWCO membrane filter. Dithiothreitol (10 mM,
Sigma-Aldrich, USA) and iodoacetamide (50 mM, Serva,
Germany) in triethylammonium bicarbonate buffer
(25 mM, Sigma-Aldrich, USA) were used for reduction
and alkylation, respectively. Proteins were then digested
with trypsin (Promega, USA) in 1:50 ratio, for one hour,
at 37 °C and then overnight at 25 °C. After centrifuga-
tion, the eluate with digested peptides was evaporated
(DNA120 SpeedVac, Thermo Savant, USA), peptide pel-
let was resuspended in 0.1 % aqueous formic acid
(Sigma-Aldrich, USA) which serves as a mobile phase
for liquid chromatography (UltiMate 3000 RSLCnano,
Dionex -Thermo Scientific, USA). For separation and
elution of peptides, 2-h gradient with increasing (0 min -
4 %, 4 min - 4 %, 98 min - 45 %, 98.5 min - 90 %,
112 min - 90 %, 112.5 min - 4 %, 120 min - 4 %) concen-
trations of acetonitrile (0.1 % formic acid in acetonitrile,
Sigma-Aldrich, USA) at a flow rate of 300 nl/min was
used. Peptides were separated on a 25 cm column (Ac-
claim PepMap RSLC C18, 2 μm, 100 Å, 75 μm I.D.,
Thermo Scientific, USA). uHPLC was connected to
EASY-Spray ion source and Orbitrap Velos Pro mass
spectrometer (Thermo Scientific, USA). A survey scan
over the m/z range 390–1700 was used to identify pro-
tonated peptides with charge states of at least 2, which
were automatically selected for data-dependent MS/MS
analysis and fragmented by collision with helium gas.
Ten fragment mass spectra after each full scan were re-
corded. Measured spectra were then searched using
Proteome Discoverer (version 1.4, Thermo Scientific,
USA) software with Mascot (Matrix Science, USA) or
Sequest HT (Thermo Scientific, USA) as a searching al-
gorithm. Oxidation of methionine as a dynamic, and car-
bamidomethylation of cysteine as a static modification
was used. Precursor and fragment mass tolerances were
set up as 10 ppm and 0.5 Da, respectively. Swiss-Prot
database for Salmonella strain was used (based on 2014/
06 release) in Mascot and Uniprot database for Salmon-
ella strain (from 2013/04) was used in Sequest HT. Only
peptides with a false discovery rate less than 0.05 were
considered as well identified. Proteins that were uniquely
found in each sample - proteins bound to the IgG frac-
tion from sera from either vaccinated or infected ani-
mals, but not from control pigs were then pinpointed as
candidate antigens for serological discrimination.
Recombinant protein preparation and its purification
Appropriate primers (Tab. 1) for each selected protein were
designed using NCBI/Primer-BLAST. PCR reaction with
Salmonella DNA (supernatant from washed cell culture
heated in distilled water for 10 min at 95 °C) as a template
and Taq polymerase (Plain PP Master Mix, Top Bio, Czech
Republic) was carried out. PCR products were purified
(MinElute PCR Purification Kit, Qiagen, Germany), then
cloned into the pTrcHis-TOPO vector (Invitrogen, USA)
and recombinant proteins were expressed in TOP10 One
Shot chemically competent E. coli cells (Invitrogen, USA).
IPTG was used as an inducer of the expression. Recombin-
ant proteins with N-terminal His-Tag were isolated on
HiTrap Chelating HP columns (GE Healthcare, UK) with
attached nickel ions. Briefly, an overnight E. coli culture in
LB broth (Invitrogen, USA) was centrifuged and washed in
PBS (Dulbecco’s, Lonza, Switzerland) and cells were dis-
rupted by sonication (Sonopuls HD 3100, Bandelin,
Germany). After centrifugation, supernatant with proteins
was transferred to a binding buffer (0.02 M sodium phos-
phate, 0.5 M NaCl, 5 mM imidazole, pH 7.4) using desalt-
ing columns (PD-10, Sephadex G-25 M, GE Healthcare,
UK). Metal-chelate affinity chromatography was performed
on an FPLC system (Pharmacia, Sweden). After washing
with a buffer containing an increased concentration of
imidazole (40 mM), His-Tagged proteins were finally eluted
with the elution buffer (0.02 M sodium phosphate, 0.5 M
NaCl and 250 mM imidazole, pH 7.4).
If further purification was needed, we performed a pre-
parative electrophoresis in a polyacrylamide gel (Model
491 Prep Cell, BioRad, USA) according to the manufac-
turer’s protocol. For protein expression and purity verifica-
tion, SDS-PAGE and western blot with a mouse anti-
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HisTag antibody (Pierce, Thermo Scientific, USA) was
used.
Western blot
Purified recombinant proteins were resolved on a 10 %
SDS-PAGE gel and transferred to PVDF membranes
(Amersham, GE Healthcare, UK), which were subse-
quently blocked in 1 % casein hydrolysate (Imuna, Czech
Republic) overnight at 4 °C. The membranes were incu-
bated with 100× diluted porcine sera for one hour at
room temperature (RT), washed in PBS with 0.05 %
Tween-20 (PBS/T, Serva, Germany) and then incubated
(one hour, RT) with goat anti-pig IgG conjugated with
HRP (Bethyl Laboratories, USA). After a washing step,
the protein bands were visualized with diaminobenzidine
(Sigma-Aldrich, USA). Western blots were performed
with group-specific pooled sera samples.
ELISA assay
Purified recombinant proteins in 0.05 M sodium
carbonate-bicarbonate buffer (pH 9.6) were coated (4 °C
overnight) on microtiter plates (MaxiSorp, Nunc,
Denmark) that were blocked afterwards with 1 % casein
hydrolysate in PBS/T (30 min). The plates were subse-
quently incubated (one hour, RT) with 100× diluted por-
cine sera, washed with PBS/T and then incubated (one
hour, RT) with goat anti-pig IgG conjugated with HRP
(Bethyl Laboratories, USA). After a washing step, the
colour was developed by adding the chromogenic sub-
strate TMB Complete (Test-line, Czech Republic) and
the reaction was stopped with 2 M sulfuric acid (Penta,
Czech Republic). The absorbance was measured at
450 nm on Synergy H1 (Biotek, USA). IgG antibody re-
sponse to LPS was determined by commercially available
Pig Screen ELISA (Qiagen, Germany). The individual
serum samples were tested in duplicate by ELISA. Posi-
tive thresholds in time course graphs were counted as
an average plus three standard deviations of all control
samples and time zero samples of respective groups [11].
Positive thresholds for LPS commercial kit were pro-
vided by a manufacturer.
Statistical evaluation
Densities of western blot bands were calculated using
ImageJ software (ver. 1.48). Differences between groups
in ELISA assays were evaluated by ANOVA with Dunn’s
post test using GraphPad Prism (ver. 5). All graphs were
also made using GraphPad Prism software (GraphPad
Software, USA).
Results
Protein expression profiles in different media
At first, we examined protein expression profiles of Sal-
monella growing in different cultivation media. LB broth
was used as a standard growth medium for cultivation of
bacteria. For comparison, brain heart infusion (BHI), a
highly nutritious medium was used as a vaccine prepar-
ation medium when the vaccine was proved to be pro-
tective [9]. From the whole-proteome mass spectrometry
analysis, we observed the differences in LB and BHI cul-
tures in relative quantities of several proteins that belong
to the SPI-1 and SPI-2 loci which are important for the
virulence of Salmonella. Relative quantification was
attained using spectral counting and, in Tab. 2, it is
shown as PSMs (peptide spectrum matches) for all pep-
tides which identify the protein. Since PSMs depend on
the length of a protein, the comparison of PSM value for
the same protein between each medium is more inform-
ative rather than the absolute number. Note that the
shown proteins are only representatives of the SPI-1 and
SPI-2 loci and not the complete list.
All selected SPI-1 proteins were expressed in much
higher amounts in LB medium than in BHI medium
while proteins belonging to the SPI-2 locus were not
highly expressed in either of the media. Flagellar pro-
teins that also play an important role in the first stages
Table 1 Primer pairs of DNA sequences for used proteins (or polypeptide fragments) and their expected molecular weight
including HisTag
Protein Forward primer 5′-3′ Reverse primer 5′-3′ Expected protein molecular weight
BamB ATGCAATTGCGTAAATTACTTCTGCC TTAACGCGTAATCGCGTAGACC 45.8 kDa
FliC-frag ACGCTGAATGTGCAACAAAAATATAAGGTC ACCTTCGGCTTTACTTGCAGCG 25.8 kDa
MetQ ATGGCGTTCAAATTCAAAACCTTTGCGG TTACCAGCCTTTCACCGCGCC 33.3 kDa
PrgI ATGGCAACACCTTGGTCAGGCTATC TTAACGGAAGTTCTGAATAATGGCAGCATC 12.7 kDa
SipC ATGTTAATTAGTAATGTGGGAATAAATCCCGCC TTAAGCGCGAATATTGCCTGCGAT 46.8 kDa
SipD ATGCTTAATATTCAAAATTATTCCGCT TTATCCTTGCAGGAAGCTTTT 41.0 kDa
SseB ATGTCTTCAGGAAACATCTTATGGGGAA TCATGAGTACGTTTTCTGCGCTATC 25.4 kDa
SurA ATGAAGAACTGGAAAACGCTGCTTC TTAGTTACTCAAAATCTTAACGTAAGCGCTG 51.1 kDa
SipB ATGGTAAATGACGCAAGTAGCATTAGCCG TTATGCGCGACTCTGGCGCAGAATAAAAC 66.3 kDa
OppA ATGTCTAACATCACGAAAAAAAGTTTG TTAATGTTTGATAATATATAAGTTTTTCACATAAAT 65.1 kDa
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of an invasion were expressed in both media in high
amounts. Proteins PepN (Aminopeptidase N) and GapA
(Glyceraldehyde-3-phosphate dehydrogenase A) are
mentioned only as reference proteins.
Mass spectrometry analysis of immunoaffinity
chromatography samples
Salmonella protein lysates preparations and consecutive
immunoaffinity chromatography analyses resulted in
three sets of samples for MS identification (Salmonella
proteins bound to antibodies from control, infected or
vaccinated animals). While most of the proteins were
identified in all three samples in similar proportion, we
found several proteins that were identified in relatively
higher amounts in “post-infection” or “post-vaccination”
fraction (Tab. 3). Relative amounts are shown as peptide
spectrum matches (PSMs). Proteins SipB and SipC from
SPI-1 were found in eluates from the column with post-
infection sera while several proteins (OppA, BamB and
SurA) were predominantly bound to antibodies in post-
vaccination sera. We also included the identification of
proteins that were chosen for their involvement in the
infection process (SipD, SseB, PrgI and FliC) rather than
from immunoaffinity chromatography/MS analysis only.
Recombinant protein preparation
All proteins listed in Table 3 were prepared as recombin-
ant proteins in an E. coli expression system. The se-
quences of all proteins containing signal peptides at their
N-termini were designed without this peptide. Otherwise,
they possessed an identical sequence as naturally occur-
ring in S. Typhimurium except FliC protein. Due to an in-
ability of full-length protein expression, flagellar protein
FliC was expressed only as a 22 kDa fragment. The ex-
pression of proteins was endorsed by SDS-PAGE and con-
firmed by western blot with an anti-HisTag antibody
(Fig. 1 and Additional file 1: Figure S1). Four out of ten se-
lected proteins (MetQ, SurA, PrgI, SipC) were not
expressed in sufficient amount or purity and were not in-
cluded in subsequent serological testing.
Serological testing
Western blot
Purified recombinant proteins were then used as anti-
gens for serological analysis. After western blot, PVDF
membranes were incubated with pooled serum samples
from three animals of each group (control, infected and
vaccinated animals). As shown in Fig. 2, proteins SipB,
SipD and SseB presumed to be “post-infection” antigens
were detected by sera of infected animals with a higher
intensity than by sera of control or vaccinated animals.
On the other hand, proteins BamB, FliC-frag and OppA,
supposed to be “post-vaccination” antigens, were de-
tected by sera of vaccinated pigs with a higher intensity
than by sera of control or infected animals. Anti-HisTag
antibody was used as a positive control for recombinant
protein presence (in Fig. 2D).
ELISA assay
Based on western blot results, proteins SipB and FliC-
frag were selected for testing specific antibody response
of individual animals by ELISA method. Serum samples
from 12 animals in each group were used for measuring
antibody levels against recombinant SipB and FliC-frag
proteins.
Antibody levels against SipB protein in sera of control
animals had the values of absorbance between 0.062 and
0.126; sera of vaccinated animals had the values of ab-
sorbance between 0.075 and 0.147. The difference in ab-
sorbance between these two groups was not statistically
significant. Sera of infected pigs had the values of ab-
sorbance between 0.248 and 1.056. These values were
significantly different (P <0.01) from the two previous
groups of animals.
Antibody levels against FliC-frag proteins in sera of con-
trol animals had the values of absorbance between 0.018
and 0.271; sera of infected animals had the values of ab-
sorbance between 0.060 and 0.891. The difference in ab-
sorbance between these two groups was not statistically
Table 2 Several selected proteins belonging to SPI-1 and/or
SPI-2 locus and their relative amounts produced by S. Typhimur-





SPI-1 SipA P0CL52 37 2
SPI-1 SipB Q56019 31 4
SPI-1 SipC P0CL47 50 3
SPI-1 SipD Q56026 10 0
SPI-1 PrgI P41784 5 2
SPI-1 SptP P74873 20 0
SPI-1 SopA Q8ZNR3 16 5
SPI-1 SopB O30916 38 0
SPI-1 SopE2 Q7CQD4 5 0
SPI-1 and-2 SteA Q8ZPD7 0 0
SPI-1 and-2 SopD P40722 5 0
SPI-2 SopD2 Q8ZQC8 3 0
SPI-2 SseB Q7BVH7 0 3
SPI-2 PipB Q8ZQ59 0 1
SPI-2 PipB2 Q8ZMM8 4 0
flagellar proteins FliC P06179 132 77
FljB P52616 107 61
reference proteins PepN Q8ZQ76 48 39
GapA P0A1P0 185 279
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significant. Sera of vaccinated pigs had the values of absorb-
ance between 1.727 and 2.159. These values were signifi-
cantly different (P <0.01) from two previous groups of
animals (Fig. 3). Hence, proteins SipB and FliC-frag may
serve as marker proteins applicable for serological
discrimination between vaccinated pigs, pigs after natural
infection and pigs without any contact with S.
Typhimurium.
When compared to a non-infected group, from graphs
showing the time course of antibody response (Fig. 4) we
Table 3 Identification and relative quantification of chosen proteins in terms of Peptide Spectrum Matches for all three runs
Protein name Accession
number
PSMs (peptide spectrum matches)
Control Post-infection Post-vaccination
Cell invasion protein SipB Q56019 3, 0, 22 29, 20, 27 13, 7, 25
Cell invasion protein SipC P0CL47 5, 1, 22 30, 33, 31 7, 18, 26
D-methionine-binding lipoprotein MetQ Q8ZRN1 3, 1, 0 12, 5, 11 0, 0, 9
Periplasmic oligopeptide-binding protein OppA P06202 7, 0, 0 31, 0, 0 25, 16, 14
Outer membrane protein assembly factor BamB H9L451 0, 2, 0 0, 0, 7 7, 10, 0
Chaperone SurA Q7CR87 1, 5, 1 2, 0, 21 21, 15, 15
Cell invasion protein SipD Q56026 7, 3, 0 4, 15, 0 4, 14, 1
Secreted effector protein SseB Q7BVH7 0, 0, 0 2, 0, 0 1, 0, 1
Protein PrgI P41784 0, 2, 0 1, 2, 0 2, 0, 1
Flagellin FliC P06179 3, 22, 17 23, 29, 26 19, 17, 63
Fig. 1 Recombinant proteins expressions. Coomassie-stained gels and western blots of SipB (a) and FliC-frag (b) proteins. Time scale expression is
shown in hours post induction (0–5 h, ON - overnight). Arrows indicate the expected molecular weight of a product. Expression of other proteins
can be found in Additional file 1: Figure S1
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can see the increase of anti-SipB IgG level from the third
week of infection but not significant differences for anti-
FliC antibodies throughout the infection experiment
(Fig. 4a, b). In contrary, the vaccination does not induce
anti-SipB antibody production but anti-FliC IgGs are de-
tectable after 14 days that is the time of revaccination
(Fig. 4d, e). For comparison, we measured the level of post-
infection and post-vaccination antibodies against O-
antigens - the outer segments of surface lipopolysaccharides
using commercially available ELISA kit (Fig. 4c, f). As ex-
pected, we found a similar pattern of immunoglobulin G
production in both, infected and vaccinated groups. Add-
itionally, a concentration of IgM antibodies against SipB
protein did not exceed positive threshold after the infection.
Anti-LPS IgMs were detectable on day 7 and 14 in two and
four pigs respectively (see Additional file 1: Figure S2).
Discussion
Although the vaccination of animals against bacterial
pathogens helps to moderate the severity of infection and
is widely used in veterinary medicine, there are several is-
sues that have to be solved during the development
process and before introducing such vaccines to the mar-
ket. Besides the induction of humoral and cellular immun-
ity - the protectivity itself, in many cases, we must ensure
a proper distinction between animals after the natural in-
fection and vaccinated animals – i.e. DIVA vaccines [12].
We believe that using a vaccine with differentiability of in-
fected and vaccinated animals enable establishment of Sal-
monella control programs in pig herds. This goal is
currently not possible using the only licensed live attenu-
ated vaccine [7]. In a case of Salmonella DIVA vaccines,
several groups followed the path of a negative marker vac-
cine [7, 8], which uses a vaccine strain with a deleted gene
for an antigenic protein. Host antibodies against this pro-
tein are thus found only in naturally infected animals and
are absent in vaccinated animals. However, using live at-
tenuated genetically modified Salmonella vaccine strains
in pig herds is not straightforward. We proved inactivated
Salmonella vaccine efficiently protects suckling piglets
against infection [9] and further developed a DIVA
method whereby there is no need for using a live genetic-
ally modified organism as an antigen for a vaccine. To de-
velop DIVA assay, we decided to use a novel approach
Fig. 2 Western blots of recombinant proteins with sera. Western blots with respective density graphs of purified recombinant proteins with A –
control sera, B – post-vaccination sera, C – post-infection sera, and D – with anti-HisTag Ab
Fig. 3 ELISA assay of recombinant proteins. Graphs of IgG absorbance from ELISA assays of two recombinant proteins incubated with individual
sera of control animals (N = 12), STM infected animals (N = 12) and animals after vaccination with STM-based vaccine (N = 12)
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based on examination of the natural antibody response
against Salmonella Typhimurium after the infection and
after the vaccination with a Salmonella Typhimurium-
based inactivated vaccine. We took advantage of that Sal-
monella Typhimurium undergoes several different stages
during the infection according to its localization and to
the host immune response. Following these conditions,
bacteria change the expression of virulence and protecting
proteins [13, 14] that are subsequently exposed to the im-
mune system.
Besides proven protectivity of the used vaccine in
suckling piglets [9], we found that antibodies produced
after the infection, are indeed different from those after
the vaccination. From the immunoaffinity chromatog-
raphy and mass spectrometry, we selected the following
candidate proteins – SipB, SipC, MetQ, OppA, Bam and
SurA. Then, we added some proteins that were not de-
termined by the aforementioned method, but are known
to be involved in the infection process as they belong to
the SPI-1 or SPI-2 locus – SipD, SseB and PrgI and a
highly immunogenic flagellar protein FliC.
Proteins SipB, SipC and SipD are representatives of the
SPI-1 system which is responsible for invading the host
cells. It is well established that these proteins form a tip of
a needle structure of the type III secretion system complex
that interacts with the eukaryotic cells [13, 15]. Protein
SseB encoded by the SPI-2 locus acts as a translocator that
mediates translocation of effector proteins into the host
cells and promotes bacterial survival [16]. These proteins
are therefore crucial for virulence and are candidates for
inducing the antibody response that was also confirmed in
this work. On the other hand, when Salmonella Typhi-
murium was cultivated in vitro in BHI culture medium as
a vaccine batch, these proteins were not expressed in
amounts able to induce antibody production. SPI-1 pro-
teins were nevertheless found in high amounts when Sal-
monella had grown in LB medium. This medium is
therefore not applicable for a vaccine batch preparation
because it could induce production of the same antibodies
as after a natural infection. Nutrient-limiting conditions
provided by LB broth partially resemble in vivo environ-
ment and trigger SPI-1 proteins expression, while rich
BHI medium does not induce production of Salmonella
virulence factors. Jaradat and Bhunia [17] suggested a
similar explanation as gained from their results in differ-
ent growth conditions of Listeria monocytogenes, stating
that bacteria produce more virulence factors in a nutri-
tionally poor milieu in order to adapt to the new environ-
ment. On the other hand, bacterial virulence factors seem
to be good candidates for antibody response induction
and therefore for the vaccine protectivity in general. How-
ever, we showed that the efficacy of our vaccine prepared
Fig. 4 Time course of antibody response. The time course of IgG antibody response to SipB and FliC-frag proteins after the infection (a, b) or
vaccination (d, e). For comparison, graphs c and f show antibody response to O-antigens of Salmonella LPS. The connecting lines determine the
average of five animals randomly selected from each group
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from a culture grown in a medium not inducing the ex-
pression of SPI proteins is high [9].
In spite of the fact that flagellin has powerful immu-
nostimulatory properties and may play a role as a potent
adjuvant in a variety of anti-bacterial vaccines [18–20], it
was also shown that expression of flagellar proteins is se-
lectively repressed when Salmonella is located intracellu-
larly during the infection [21, 22]. The flagellum as an
extracellular structure on the surface of a bacterium
could be a good candidate as a post-vaccination antigen
if an appropriate growth medium capable of promoting
the expression of flagellar proteins is used. This was
proved for FliC protein fragment by western-blot and
ELISA but interestingly not by PSM spectra of immuno-
affinity eluates. We speculate this was caused by overall
high amount of anti-FliC antibodies in all samples and
the capacity of immunoaffinity columns was probably
saturated. Only western-blot and ELISA were able to
show much higher anti-FliC antibody level in post-
vaccination sera than in post-infection and control sera.
PSM for FliC in control sample was probably caused by
cross-reactivity of anti-flagellar antibodies induced by
other bacteria in control animals. The other possible ex-
planation is very high expression of FliC protein in cul-
tures and possible unspecific binding in the
chromatography column. Proteins BamB (Outer mem-
brane protein assembly factor) and OppA (Periplasmic
oligopeptide-binding protein) are located on the outer
membrane and the periplasm, respectively, which makes
them easy targets for the immune system. Although
both proteins are involved in transmembrane transport
(OppA as a permease [23] and BamB as a part of the
outer membrane protein assembly complex involved in
insertion of beta-barrel proteins [24]), their role in the
infection is not known. Interestingly, both proteins are
much less immunogenic during infection than after vac-
cination. This finding makes them together with FliC
good candidates for serological differentiation between
infected and vaccinated animals.
After successful isolation of recombinant proteins, we
tested them using western blot and ELISA with post-
infection, post-vaccination and control serum samples to
prove their ability to distinguish between infected and
vaccinated animals. Proteins SseB, SipB and SipD were
confirmed to be highly immunogenic during the infec-
tion. This is in agreement with previous findings [25,
26]. The level of antibodies against these proteins, mea-
sured as a density of bands on western blots, was, at
least, ten times higher in a group of infected animals
than in a group of control or vaccinated animals. On the
other hand, proteins BamB, OppA and FliC-frag were
confirmed to be highly immunogenic during the vaccin-
ation of pigs. The level of antibodies against these pro-
teins was, at least, ten times higher in a group of
vaccinated animals than in a group of control or infected
animals. As in the case of FliC, there is a partial discrep-
ancy with immunoaffinity chromatography results in the
case of SseB protein when it showed a similar level of
binding to post-infection and post-vaccination anti-
bodies. However, it can be explained by low expression
of SseB in cultivation media and thus possible incom-
plete saturation of all specific antibodies present in the
chromatography column.
Finally, proteins SipB and FliC-frag were selected for
ELISA assays to examine the interaction with 36 porcine
serum samples. All 12 post-infection sera exhibited
higher absorbance with the SipB protein than 12 control
and 12 post-vaccination sera. In contrast, all 12 post-
vaccination sera exhibited higher absorbance with the
FliC-frag protein than 12 control and 12 post-infection
sera. All differences were statistically significant (P
<0.01). The time-dependent onset of IgG antibody levels
against SipB after the infection, and against FliC after
the vaccination imitates the increase of IgG against sur-
face lipopolysaccharide. These two proteins are thus
considered as useful antigens for serological differenti-
ation of infected and vaccinated animals.
In general, induction of different protein expression
profiles, their potential exposure to the immune recogni-
tion machinery and subsequent specific antibody pro-
duction can be conveniently applied for the
differentiation between infected and vaccinated animals
without any intervention into the genome of an organ-
ism used as a vaccine strain.
Conclusions
Using antibodies from previously vaccinated and in-
fected animals and using immunoaffinity chromatog-
raphy and mass spectrometry tools, we identified
Salmonella proteins that induce post-infection and post-
vaccination specific antibody production. Gene cloning
and recombinant protein expression techniques were
used for antigen preparation that allows serological dis-
tinction between infected animals and animals vacci-
nated with a Salmonella-based inactivated vaccine.
This approach can be utilized in many other chal-
lenges where DIVA vaccine and a subsequent serological
assay are required, especially when genetic modification
of a vaccine strain is not desirable.
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